Equities analysts predict that Black Diamond Therapeutics (NASDAQ:REYN) will announce $839.16 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Black Diamond Therapeutics’ earnings. The highest sales estimate is $874.80 million and the lowest is $815.38 million. The company is expected to report its next earnings results on Thursday, August 6th.
On average, analysts expect that Black Diamond Therapeutics will report full-year sales of $3.21 billion for the current financial year, with estimates ranging from $3.17 billion to $3.28 billion. For the next financial year, analysts anticipate that the company will report sales of $3.26 billion, with estimates ranging from $3.18 billion to $3.35 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Black Diamond Therapeutics.
Black Diamond Therapeutics (NASDAQ:REYN) last announced its earnings results on Thursday, May 7th. The company reported $0.30 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.03. The company had revenue of $691.00 million during the quarter, compared to the consensus estimate of $695.40 million. The firm’s quarterly revenue was up 10.6% on a year-over-year basis.
Black Diamond Therapeutics stock traded up $0.59 during trading on Monday, reaching $34.89. The company had a trading volume of 332,481 shares, compared to its average volume of 851,251. Black Diamond Therapeutics has a 52 week low of $21.61 and a 52 week high of $36.00. The business’s 50-day moving average is $33.64. The stock has a market capitalization of $7.32 billion and a price-to-earnings ratio of 24.06.
Institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $26,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $29,000. Advisor Group Holdings Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $41,000. Global Retirement Partners LLC purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $41,000. Finally, Deutsche Bank AG purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $67,000. Hedge funds and other institutional investors own 25.13% of the company’s stock.
Black Diamond Therapeutics Company Profile
Reynolds Consumer Products Inc, a consumer products company, produces and sells products across cooking, waste and storage, and tableware. It operates through four segments: Reynolds Cooking & Baking, Hefty Waste & Storage, Hefty Tableware, and Presto Products. The Reynolds Cooking & Baking segment produce foil, parchment paper, and disposable aluminum pans, as well as cooker liners.
Featured Story: High-Yield Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.